Jiwei Huang, Xiaoyi Hu, Hang Wang, Jianming Guo, Hongxian Zhang, Pei Dong, Wei Xue. "Fruquintinib plus serplulimab as first-line therapy in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated efficacy and safety data from a multicenter, single-arm, phase II trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.7_suppl.422